fig6

Figure 6. Suppressing TEV release delays tumor growth and prevents loss of IFNAR1. (A) Tumor growth curve of EO771 tumor-bearing WT mice treated intravenously (iv) with vehicle, 1 mg/kg of reserpine (every other day), 2 mg/kg paclitaxel (twice a week), or both reserpine and paclitaxel (n = 5, each group); (B) ELISA for CD63 to quantify TEVs from serum of WT mice treated intravenously (iv) with vehicle, 1 mg/kg of reserpine (every other day), 2 mg/kg paclitaxel (twice a week), or both reserpine and paclitaxel with EO771 with tumors of similar size; (C) Flow cytometry analysis comparing change in mean fluorescent intensity (ΔMFI) of IFNAR1 in CD45+ cells from peripheral blood of WT mice with EO771 with tumors of similar size treated intravenously (iv) with vehicle, 1 mg/kg of reserpine (every other day), 2 mg/kg paclitaxel (twice a week), or both reserpine and paclitaxel (n = 5); (D) Tumor growth curve of 4T1-GFP tumor-bearing WT mice treated intravenously (iv) with vehicle and given vehicle chow (n = 5), iv vehicle and reserpine chow (n = 9), iv injection with 2 mg/kg paclitaxel (twice a week) and vehicle chow (n = 5), or iv injection with paclitaxel and reserpine chow (n = 5); (E) ELISA for CD63 to quantify TEVs from serum of WT mice with similar size tumor from (D); (F) Flow cytometry analysis comparing change in mean fluorescent intensity (ΔMFI) of IFNAR1 in CD45+ cells from peripheral blood of WT mice with EO771 with tumors of similar size from (D); Quantitative data are represented as mean ± SEM; P values: * P < 0.05; ** P < 0.01; *** P < 0.001, and ns for not significant from Anova test (panels A and B) or Student’s t test (panels B, C, E, and F).